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Lung cancer is by far the leading cause of cancer-related mortality worldwide regardless of sex, and 
has a dismal overall 5-year survival rate of approximately 15%. More than 85% of all lung cancers 
are non-small cell lung cancer (NSCLC), and about 50% of these are adenocarcinomas. Targeted 
treatment has shown promising results in treating certain types of NSCLC, but the overall survival 
is still frustratingly low. PAX6 is a transcription factor that has very recently been shown to have 
positive effect on survival when expressed in lung cancer. We want to identify potential target 
genes for PAX6 that can explain this observation, and possibly provide a greater understanding of 
the molecular mechanisms involved in the pathogenesis of non-small cell lung cancer. PAX6 
expression was knocked-down in lung cancer cell lines, and expression of some cancer-associated 
genes in PAX6-knockdown samples was compared with expression in control samples. Expression 
was studied on gene level, using comparative qPCR and on protein-level, using western blot. Cell 
behaviour after PAX6 knockdown was studied in real-time using two different systems designed for 
this purpose. Our results show that PAX6 does regulate a number of cancer associated genes, and 





NSCLC Non-small cell lung cancer 
PAX  Paired box 
DNA  Deoxyribonucleic acid 
cDNA  Comparative DNA 
RNA  Ribonucleic acid 
mRNA Messenger RNA 
PD  Paired domain 
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TAD  Transcriptional activation domain 
TF  Transcription factor 
ICW  In-Cell western 
GFP  Green fluorescent protein 
siRNA  Small interfering RNA 
SCR  Scrambled 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
WB  Western blot 
bp  Base pair 
Ct  Cycle threshold 






Cancer is a general term for a large group of diseases that can affect any part of the body, and the 
main hallmark of cancer is loss of growth control. Other terms used are malignant tumours and 
neoplasms. One defining feature of cancer is the rapid creation of abnormal cells that grow beyond 
their usual boundaries, and which can then invade adjoining parts of the body and spread to other 
organs, a process referred to as metastasis [1]. Metastases are the major cause of death from cancer. 
Cancer typically arises from one single cell, and the transformation from a normal cell into a 
tumour cell is a multistage process, typically from a pre-cancerous lesion to malignant tumours [2]. 
Lung cancer is a cancer that is characterized by uncontrolled malignant cell growth in lung tissue 
(lungs and bronchia). Lung cancer is by far the leading cause of cancer-related mortality worldwide 
regardless of sex, and has a dismal overall 5-year survival rate of approximately 15% [3]. Earlier, 
lung cancer in men was more frequent than in woman, but in the past years this difference has been 
evened out – probably as a consequence of the increase in women smokers, and lung cancer now 
kills more woman than does breast cancer, ovarian cancer and uterine cancer put together [4]. 
Traditional treatment of lung cancer includes surgery, radiation, chemotherapy, palliative care, 
alone or in combination in an attempt to cure or lessen the adverse impact of malignant neoplasm 
originating in lung tissue [5]. In the last decade there has been achieved significant progress in 
research in the molecular mechanisms involved in lung cancer, and new drugs are currently in use, 
tested and developed. Disappointingly, not much improvement in survival has been achieved even 
with the most recent expensive molecular therapies, such as anti-angiogenic drugs. The poor 
survival rate of patients with lung cancer makes specialized/individualized medicine a potential 
revolution in the treatment of lung cancer. 
Lung cancers are classified according to histological type. This classification has important 
implications for clinical management and prognosis of the disease. The vast majority of lung 
cancers are carcinomas—malignancies that arise from epithelial cells. The two most prevalent 
histological types of lung carcinoma, categorized by the size and appearance of the malignant cells, 
are non-small cell lung carcinoma (NSCLC) and small-cell lung carcinoma (SCLC) [6]. Small-cell 
lung carcinoma (SCLC) is less common than non-small cell lung cancer, and most cases arise in the 
larger airways (primary and secondary bronchi), grow rapidly and become relatively large [3]. 
7 
 
Non-small cell lung cancer 
About 85% to 90% of lung cancers are non-small cell lung cancer. There are three main subtypes of 
NSCLC, and the cells in these subtypes differ in size, shape, and chemical makeup when looked at 
under a microscope. But they are grouped together because the approaches to treatment and 
prognosis are very similar [7]. The most common types of NSCLC are adenocarcinoma, squamous 
cell carcinoma and large cell carcinoma, but there are several other types that occur less frequently, 
and all types can occur in unusual histologic variants and as mixed cell-type combinations [7].  
Adenocarcinoma of the lung is the most frequent histological form of lung cancer, and it contains 
several distinct malignant tissue architectural, cytological, or molecular features, including gland 
and/or duct formation and/or production of significant amounts of mucus [3].  
Squamous cell lung carcinoma is a cancer of a type of epithelial cell, the squamous cell. Squamous 
cell carcinoma lesions are thought to originate from uncontrolled division of cancer stem cells of 
epithelial lineage or characteristics [3]. Accumulation of these cancer cells cause a microscopic 
focus of abnormal cells that are, at least initially, locally confined within the specific tissue in which 
the progenitor cell resided. This condition is called squamous cell carcinoma in situ, and it is 
diagnosed when the tumor has not yet penetrated the basement membrane [3]. 
Large-cell lung carcinoma is a heterogeneous group of undifferentiated malignant neoplasms 
originating from transformed epithelial cells in the lung. Large-cell lung carcinoma is a diagnosis of 
exclusion made after ruling out the presence of components of squamous cell lung carcinoma, 




Molecular mechanisms in NSCLC 
The fact that lung cancer is a highly heterogeneous form of malignancy has become more apparent 
over the last decade. This group of malignant tumours are in general associated with high degree of 
aggressiveness, and a poor prognosis. However, the molecular modifications driving lung cancer 
progression have over the last few years become clearer, and the discovery of these mechanisms has 
resulted in specialized targeted therapies with tyrosine-kinase inhibitors (TKIs), especially for the 
epidermal growth factor 
receptor (EGFR), which is 
mutated in a significant 
numbers of non-small cell 
lung cancers [8]. The current 
approach is to divide different 
type of cancers in to 
molecular subtypes, which is 
defined as tumours 
harbouring the same set of 
molecular defects and their 
associated pathways [9]. 
 
The epidermal growth factor receptor (EGFR) is a transmembrane protein in the ErbB family of 
tyrosine kinases, and it binds to epidermal growth factor (EGF) and other growth factors to activate 
[8]. Activation of the receptor triggers the tyrosine kinase activity, which in turn activates 
downstream pathways, including the Akt/PI3K and the Ras/MAPK pathways, leading to DNA 
synthesis and cell proliferation [9]. The EGFR has indeed been shown to be dysregulated by various 
molecular mechanisms in NSCLC, including overexpression, amplification or by mutations [10]. 
The most common mutations of the EGFR is the in-frame deletion of exon 19 (44% of EGFR 
mutations) and the single amino acid change L858R (41% of EGFR mutations) [10]. However, in 
the case of squamous cell carcinoma, mutations in the EGFR is relatively rare (<3.6%) [9]. 
  
Figure 1: The most common molecular pathways in lung cancer (modified from West L, et al. 2011) 
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Mutations in the K-ras gene are another powerful driver in lung cancer progress. The K-ras protein 
possesses essential GTPase activity, and belongs to a family of GTPases that are involved in 
regulation of cellular behaviour in response to extracellular stimuli [9]. The K-ras pathway regulates 
several processes, such as proliferation, differentiation, adhesion, apoptosis and migration [11]. The 
oncogenic effect of K-ras is due to point mutations leading to constitutive activation of K-ras 
protein via alterations in the GTP-binding domain, preventing the conversion of GTP to GDP [11]. 
Alterations in the c-MET pathway also have oncogenic effects in NSCLC. Mutations in the c-MET 
pathway is characterized by dysregulation of mesenchymal-epithelial transition factor receptor 
tyrosine kinase (c-MET), which is a proto-oncogene encoding the tyrosine kinase membrane 
receptor hepatocyte growth factor receptor (HGFR) [12]. Dysregulation of this pathway leads to 
increased cell proliferation, cell survival, angiogenesis, invasion and metastasis. This dysregulation 
may occur via a variety of mechanisms, including c-MET overexpression, activation, 
overexpression of the hepatocyte growth factor ligand (HGF) and gene amplification. [13]. 
Aberrations in the AKT/PI3K pathway also constitute effects in cancer progression. PI3K acts as an 
antagonist on the lipid phosphatase PTEN to balance the amount of the two signalling molecules 
PIP2 and PIP3 [9]. Upon growth factor stimulation, PI3KCA is triggered, leading to increasing 
PIP3 levels which in turn drives phosphorylation of AKT and its downstream processes [9]. In lung 
cancer, the amplification of the PI3KCA gene occurs at a much higher rate than does activating 
mutations. 
Dysregulation in the vascular endothelial growth factor (VEGF) pathway is another important 
driver in lung cancer progression. The VEGF pathway regulates vascular angiogenesis, and tumours 
exploit this pathway to promote self-survival and proliferation [9]. An important downstream effect 
of the VEGF pathway is the activation of B-cell lymphoma 2 (Bcl-2), which is an anti-apoptotic 
regulator protein that has been associated with a number of cancers, including lung cancer [14]. The 
VEGF is the ligand for the vascular endothelial growth factor receptor (VEGFR), which is an 
important signalling protein involved in vasculogenesis (the formation of new blood vessels 
occurring by a de novo production of endothelial cells) and angiogenesis (the formation of new 
blood vessels from pre-existing vessels). 
Another subtype which has been observed, predominantly, in adenocarcinomas, includes the 
EML4-ALK oncogene. EML4-ALK is a fusion oncogene, consisting of echinoderm microtubule-
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associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) [15]. This fusion 
oncogene creates a transforming tyrosine kinase, with nine unique variants currently identified, of 
which several have been found to play roles in lung cancer progression [16]. 
 
The Paired box genes 
The Paired box genes (PAX-genes) comprise a family of key transcription factors that play essential 
roles during development as tissue specific trans-activating regulators. The PAX-genes are defined 
with a 128 amino acid long paired domain, encoding a unique DNA-binding motif [17]. The paired 
box was first identified in three segmentation and two tissue-specific genes in Drosophila, and 
homologs have been found in a variety of vertebrates and invertebrates [18]. PAX expression is 
observed primarily in conjunction with embryo development, where they promote cell proliferation, 
cell differentiation, cell migration and survival [19]. In most tissues, PAX expression is 
reduced/terminated as the embryo development is complete, but some tissue continue to express 
PAX genes also after embryogenesis [19]. The PAX genes function often by binding to enhancer 
sequences on the DNA, and subsequently modify transcriptional activity of downstream genes [20]. 
The transcription factor PAX6 
PAX6 is a highly conserved transcription factor comprised of two DNA binding domains; a paired 
domain (PD) and a homeodomain (HD), which can bind DNA independently or they can act 
together to mediate transcription [21]. The paired domain is a bipartite binding domain and is 
composed of a N-terminal and a C-terminal subdomain (NTS and CTS) which bind two distinct 
half-sites in adjacent minor 
grooves of the DNA helix 
[22]. The paired domain 
appears to be more 
important for specific DNA 
binding and its biological 
consequences than the 
homeodomain [22]. The C-
terminal part of PAX6 
functions as a transcriptional activation domain (TAD). The PAX6 transcription factor has two 










Figure 2: Schematic presentation of PAX6 and its isoforms. A) The PAX6 gene. B) The 





containing a 14 amino acid insertion in the N-terminal part of the PD (Figure 1B), resulting in a 
different DNA binding specificity [23], and the PAX6 ΔPD isoform lacks the PD domain, and 
consists only of the HD domain and the TAD domain. Tissue-specific transcription and alternative 
splicing of PAX6 mRNA is controlled by a complex regulatory mechanism, and PAX6 has an 
ability to participate in multiple molecular interactions [24]. 
Function 
PAX6 plays a central role in the organogenesis of the central nervous system, visual and other 
sensory organs, as well as endocrine part of the pancreas. Several studies have shown that PAX6 is 
essential for morphogenesis of the eye, from its earliest stages and subsequent formation of all 
major ocular tissues [25]. It also plays a key role for endocrine cell differentiation and function, as it 
has been shown that PAX6 mutations are associated with a diabetic phenotype, showing a 
significant decrease in insulin-positive cell number [26]. From the very discovery of PAX6, its 
function in development has been studied by examining the phenotype and gene expression profiles 




Transcription factors and cancer 
In short, transcription factors are DNA-binding proteins that control the transcription of genetic 
information from DNA to mRNA, yet these proteins do not have enzymatic activity. Transcription 
factors utilize this function unaided or as part of a larger protein complex. The main feature of TFs 
is their DNA-binding domains which bind to specific target sequences in proximity, or directly 
within, the gene(s) they regulate, and they are able to promote or inhibit transcription, mainly by 
initializing or blocking recruitment of RNA polymerase to the site of transcription [27]. 
There are three most studied and known groups of transcription factors which are of importance in 
cancer. The first group of transcription factors are the steroid receptors, which include the oestrogen 
receptor (important in breast cancer) and the androgen receptor (important in prostate cancer) [28]. 
The second group of cancer associated transcription factors are resident nuclear proteins, which are 
activated by serine kinase cascades. An example is the AP-1 transcription factor, which is activated 
through the JNK pathway, and has importance in cell proliferation and apoptosis [29]. The third 
group is the dormant cytoplasmic transcription factors, whose activation is normally initiated 
through receptor-ligand binding on the cell surface, and despite the divergence in detail in this 
group, they are similar in that a protein-protein interaction on the cell surface is triggering the 
cytoplasmic event, which in turn results in the transportation of proteins to the cell nucleus causing 
increased transcription in association with other proteins that effect the initiation of gene 
transcription [30]. Overexpression and/or uncontrolled activity of one or more transcription factors 
from within these groups is showed to have influence on survival, uncontrolled growth and 




Known targets of PAX6 
The role of PAX6 in the development of brain, eyes, nose and pancreas during embryogenesis is 
well known, but it also has a poorly understood role in cancer initiation and/or tumor progression. 
The expression of PAX6 is observed in many human cancer cell lines and has been detected in 
clinical samples of at least three different types of cancer. It appears to participate in control of cell 
proliferation, invasion, apoptosis and also other functions. However, relatively little is known about 
which genes the PAX6 transcription factor regulates in regard to cancer. One has to remember that 
a particular TF might regulate a given gene in one tissue and have no effect in another tissue. The 
first and earliest group of PAX6 target genes include a group belonging to the anatomical locations 
where PAX6 is expressed during embryogenesis. Table 1 shows a list of target genes, and where 
they are expressed. 
Table 1: List of some PAX6-regulated genes 
Location Gene Reference 
Brain 
L1CAM Chalepakis et al., 1994 
NCAM Holst et al., 1997 
Aldolase C Skala-Rubinson et al., 2002 
Optimedin A Grinchuk et al., 2005 
R-cadherin Andrews et al., 2003 
Delta-cathenin Duparc et al., 2006 
Neurogenin 2 Scardigli et al., 2003 
Eye 
Crystallines Cvekl et al., 2004 
Six3 Goudreau et al., 2002 
L-maf Reza et al., 2002 
α1+ α2 integrins Duncan et al., 2000 
Pancreas 
Insulin, glucagon and 
somatostatin 
Sander et al., 1997 
Lens 
Cspg2, Mab21l2, Olfm3, 
Spag5 and Tgfb2 
Wolf et al., 2009 
Hindbrain Unc5h1 and Cyp26b1 
Numayama-Tsuruta 
et al., 2010 
Forebrain 
Delta-catenhin, Satb2, 
Nfia, AP-2y, NeuroD6, 
Ngn2, Tbr2, Bhlhb5 
Duparec et al., 2006 
 
In addition to the important role of PAX6 in embryogenesis, it is also expressed in some tissues in 
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adult organism, and has been associated with stem cells in the eye and brain. Furthermore, it is also 
expressed in several tumours in the brain, pancreas and eye [31-33]. 
PAX6 and cancer 
PAX6 and other members of the PAX family are often expressed in mammalian cancer tissue where 
PAX6 normally is not endogenous expressed [34]. In normal tissue, the function of PAX6 is 
associated with regulation of the cell cycle, cell differentiation and cell proliferation [35]. The 
presence of PAX6 in glioblastomas has been shown to be positive for the clinical outcome, where 
PAX6 has been shown to repress the expression of MMP2 (a proteinase involved in the breakdown 
of extracellular matrix), and to make the cells more sensitive to reactive oxygen species (ROS) [32, 
36]. Tumour suppressor function was proposed for PAX6 by Robson et al., 2006, though only in a 
limited number of tissues this function is showed to be fulfilled through inhibition of cell 
proliferation, invasion and angiogenesis [37]. In contrast, PAX6 knockdown induces apoptosis in 
pancreatic cancer cells, and expression in pancreatic cancer is thought to prevent cell 
differentiation, and thus promote tumor growth [38]. Even though PAX6 is expressed in several 
human malignant tumours, and the effects on proliferation, invasion, apoptosis and other functions 
related to cancer have been studied, little is known about which cancer associated genes are 
regulated by PAX6. 
In a recent study of malignant glioma cells, PAX6 was found to up regulate the expression of the 
FABP7 gene, which encodes an intracellular lipid binding protein expressed in radial glial cells 
during brain development [39]. The expression of this gene in malignant cells that normally don’t 
express it results in increased cell migration, while suppression of FABP7 in malignant cells that 
normally express this gene, results in decreased cell migration [40]. In grade IV astrocytoma 
tumours, expression of FABP7 correlates negatively with patient survival [41], rendering PAX6 a 
driver in the progression in this type of cancer. Unpublished results from Kiselev, Mikkola et al., 
have also verified several cancer associated genes regulated by PAX6. Table 2 shows a list of these 
genes and a short description their function.  
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Table 2: Cancer-associated genes regulated by PAX6 
Gene Function 
BRCA2 Tumor suppressor gene. 
RALB 
GTP-binding protein that belongs to the small GTPase 
superfamily and Ras family of proteins. 
SPHK1 
Lipid messenger with both intracellular and extracellular 
functions. Intracellularly it regulates proliferation and survival, 
and extracellularly it is a ligand for EDG1. 
DKK3 Has function as an antagonist in the Wnt signalling pathway 
TGFBI 
A protein is induced by transforming growth factor-beta and acts 
to inhibit cell adhesion. 
VEGFA 
A glycoprotein that plays a significant role in neurons and is 
considered to be the main, dominant inducer to the growth of 
blood vessels. 
 
PAX6 and lung cancer  
According to unpublished novel results by Kiselev and Busund, immunohistochemical staining 
detects PAX6 expression in at least 25% of formalin-fixed paraffin-embedded tissue samples of 
human NSCLC. No previous reports of PAX6 in lung cancer are known in the literature. Expression 
was found to be restricted to the periphery of the tumour, mainly near the area of contact between 
malignant and normal tissue.  Survival analysis showed that PAX6-positive patients had higher 
chances for survival then PAX6-negative counterparts. This effect was more prominent for 
squamous cell tumours. Expression of PAX6 has been also detected in an adenocarcinoma-derived 




Aim of study 
The aim of this study was to get a better understating of which molecular mechanisms are regulated 
by the transcription factor PAX6 in non-small cell lung cancer (NSCLC). Unpublished results have 
confirmed the expression of PAX6 in some cases of NSCLC, and a better understating of which 
genes and functions that are regulated by this transcription factor in NSCLC could in future 
perspectives have value in designing new targeting anti-cancer drugs, or understanding failures of 
existing therapies. On the background of this, we sought to identify novel cancer-associated target 
genes for PAX6 in lung cancer by studying the effects on the knockdown of PAX6 in lung cancer 
cell lines. We also wanted to study the possible effects of PAX6 knockdown on proliferation, 




Materials and Methods 
Materials 
Table 3: Buffers and solutions 
Material Content Manufacturer Purpose 
ddH2O Double distilled water  Various 
1X PBS 137 mM Nacl, 2.7mM KCl, 10mM 
Na2HPO4, 2mM KH2HPO4, pH 7.4. 
 Washing of cells, 
western blotting. 
TBS 25 mM Tris, 150 mM NaCl, 2 mM 
KCl, pH 7.4. 
 Western Blotting 
TBST TBS + 0.1% Tween 20  Western Blotting 
NuPage 20 × running 
buffer 
Working dilution: 1:20 Invitrogen SDS-PAGE 
LDS sample buffer 40 μl 4× NuPAge LDS buffer, 50 μl 
H2O, 10 μl reducing agent. 
Invitrogen SDS-PAGE 
Blotting buffer 800 ml distilled H2O, 200 ml 





Blocking buffer Not disclosed by manufacturer Odyssey® Blocking WB-
membrane 
3.7% formaldehyde 5 ml 37% formaldehyde, 45 ml 1X 
PBS. 
 In-Cell western 
0.1% Triton washing 
solution 
5 ml 10% Triton X-100, 495 ml 1X 
PBS 
 In-Cell western 
70% ethanol 70 ml absolute alcohol + 30 ml ultra-
pure water. 
 RNA isolation 
Buffer RLT Not disclosed by manufacturer. QIAGEN® RNA isolation 
Buffer RW1 Not disclosed by manufacturer. QIAGEN® RNA isolation 
Buffer RPE Not disclosed by manufacturer. QIAGEN® RNA isolation 
Sample reducing agent 
(10X) 
500 mM DTT at a ready-to-use 10X 






Not disclosed by manufacturer Invitrogen SDS-PAGE 
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Table 4: Cell line materials 
Material Content Manufacturer Purpose 
FBS Fetal Bovine Serum Gibco® Serum-supplement 
for cell growth 
Penicillin-Streptomycin 5000 units/ml of penicillin and 
5000 µg/ml of streptomycin. 
Gibco® Prevent bacterial 




 L-glutamine, sodium 
bicarbonate and phenol red. 
SIGMA® Cell growth 
Growth medium: 
Complete RPMI-1640 
RPMI-1640 with 10% FCS and 
1× Penicillin/Streptomycine. 
SIGMA® Cell growth 
Growth medium: 
Opti-MEM® 




Opti-MEM® with 10% FCS and 
1× Pen/Strep. 
SIGMA® Cell growth 
Trypsin 0.25% Trypsin in PBS, 0.05% 
Na2-EDTA 
SIGMA® Splitting cells 
 
 
Table 5: Human cell lines used 
Cell line Organ Disease Reference Purpose Media 
NCI-H460 Lung Non-small cell lung 

















Table 6: Transfection reagents 
Reagent Manufacturer Purpose 
Lipofectamine
TM
 2000 Invitrogen 
Cat. # 11668-019 
siRNA-based gene 
knockdown experiments. 
PAX6 siRNA Ambion 
Cat. # 4392420 
Knock down expression of 
PAX6. 
Scramble (SCR) siRNA Ambion 
Cat. # 4404021 
siRNA negative control. 
 
Table 7: qRT-PCR reagents 
Reagent Manufacturer Purpose 
SYBR green Brilliant II 






Table 8: qPCR primers 
Gene Forward primer (5’  3’) Revers primer (5’  3’) 
PAX6 CAACTCCATCAGTTCCAACG TGGATAATGGGTTCTCTCAAACTCT 
TGFBI TGAAATCCTGGTTAGCGGAGGCAT ACGCCATTTGTGGCCATGATGT 
VEGFC AGGCCAACCTCAACTCAAGGACA CCCGTGGCATGCATTGAGTCTTT 
VEGFA GGTGCCCCAAGCAATACAAGCAT CACACCTTGCTCCAATGTAGCCT 
VEGFD ATGCAGGCTGAGGCTCAAAAGTT GGCTGCACTGAGTTCTTTGCCAT 
VEGFR1 ACCGAATGCCACCTCCATGTTTG ATCTTGAGCGAGGCCTTGGGTTT 
VEGFR2 ATCTGCCCAGGCTCAGCATACAA ACCCTTTGCTCACTGCCACTCT 
VEGFR3 ACAAGAAAGCGGCTTCAGCTGTA ACAGCTCCCCATACTCGCTGTT 
PDGFA CGCGACCACAAGCCTGAATCC TGGTTGGCTGCTTTAGGTGGGT 
AKT3-1 CACCTTCCGACATCCCAGACCA AGCAGCAACAGCATGAGACCTT 
AKT3-2 TCTGAGGACCGCACACGTTTCTAT TGGCTGCATCTGTGATCCCTTCT 
PTEN TGTTCAGTGGCGGAACTTGCAAT CACAGGTAACGGCTGAGGGAACT 
WNT2b-1 ATGTTGGATGGCCTTGGAGTGGT ACGCTGACTGTGTAGGTATGCCA 
WNT2b-2 TGTCCGTTTTGCCAAGGCCTTC ACTCACGCCATGGCACTTACACT 
v-MYC GCAGCTGCTTAGACGCTGGATTT AATACGGCTGCACCGAGTCGTAG 
EIF4H TGTGGACATTGCAGAAGGCAGAA TTGAAGTCATCCCGGGAATCCCA 
SFRP2 ACATGCTTGAGTGCGACCGTTT GCAGGCTTCACATACCTTTGGAG 
ANG1 ACACTGGGACAGCAGGAAAACAGA TTTAGATTGGAGGGGCCACAAGCA 
BMP2 TGTATCGCAGGCACTCAGGTCA CCGGGTTGTTTTCCCACTCGTTT 
MXD1 TTCGCTTGTGCCTGGAGAAGTT TGGTCGATTTGGTGAACGGCTTT 
MAX-1 CGGGCCCAAATCCTAGACAAAGC TTCTCCAGTGCACGGACTTGCT 
MAX-2 ACGAAGAGCAACCGAGGTTTCAA TGAGTCCCGCAAACTGTGAAAGC 
BTC GGTGCCCCAAGCAATACAAGCAT CACACCTTGCTCCAATGTAGCCT 
TF1 GGCGCTTCAGGCACTACAA TTGATTGACGGGTTTGGGTTC 
TFPI1 TTGTGCATTCAAGGCGGATGA TCTTCGCACTGTCGAGTGAAA 





Table 9: Antibodies 
Antibody Dilution Manufacturer 
Mouse anti-PAX6 








IRDye 800CW Donkey 
anti-Goat 
1:10000 LI-COR® 
IRDye 800CW Donkey 
anti-Mouse 
1:1000 LI-COR® 





Cell Culture techniques 
To avoid contamination by microorganisms it is very important to use proper aseptic techniques to 
minimize such contamination. For this reason all cell related work was performed inside a LAF 
cabinet, class II in a separate cell lab. Gloves and protective coats were always used in the cell lab. 
Before and after working in the LAF cabinet, the surfaces were cleaned with 70% ethanol. 
Equipment used in the cabinet was also cleaned with 70% ethanol before use.  
Thawing cells 
Complete medium was pre-warmed before selected cells were removed from the liquid nitrogen 
tank and placed in the incubator. After no more than 10 minutes the cell-suspension was transferred 
from the cryo-tube to a T-25 culture flask together with 5 ml of pre-warmed complete medium. The 
media was changed the next day to remove all traces of DMSO (a freezing agent), which can be 
toxic to the cells. 
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Trypsination of cells 
When splitting cells for further cell work or sub-cultivation, they need to be trypsinised to detach 
from the flask surface. Media is removed and cells are washed with 10 ml (for T-75 flask) PBS to 
remove traces of serum, which contain inhibitors of trypsin. The PBS is removed, and 1 ml trypsin 
is added and distributed over the surface. The flask is placed in the incubator for optimal reaction 
temperature for the trypsin. After 5 minutes the flask was checked under a microscope to confirm 
cell-detachment. If all the cells had not detached, the flask was put back in incubator and checked 
every two minutes until all cells had detached. Despite various protocols suggesting pounding the 
flask against the palm of hand to accelerate detachment, we did not utilize this. In our experience 
this rough treatment of cells caused them to clump, and they hence became difficult to re-suspend. 9 
ml of complete media was added to the flask, and distributed over the surface 3-4 times to ensure all 
cells had detached. The cell suspension was gently pipetted up and down until all clumps had 
broken up. Cells were typically sub-cultivated in a ratio of 1:10. 
Transfecting siRNA 
Transfection is a method used to introduce nucleic acids into living cells. In this study 
Lipofectamine®2000 from Invitrogen was used to get siRNAs (small interfering RNAs) into cells. 
Lipofectamine is a cationic liposome formulation that binds to the negatively charged nucleic acids, 
and then fuses through the cell membrane transporting the nucleic acids into the cell[42]. Inside the 
cell, siRNAs targets and interferes with the expression of genes with complementary sequences. In 
this study, siRNA targeting PAX6, and its isoforms, was transfected into different cell lines. 
Scrambled (SCR) siRNA was transfected as negative control. Cells were grown to 50-70% 
confluence in 6-well dishes before media was removed and replaced with 1 ml of transfection mix 
per well. The transfection protocol has been thoroughly optimized and the efficiently carefully 
evaluated. 
 Transfection mix (1 ml): 
 50 µl Opti-MEM 
 2 µl Lipofectamine®2000 
 2 µl siRNA 
 Wait 15 minutes 




In a 6-well dish, 3 wells were transfected with PAX6 siRNA and 3 wells with SCR siRNA. Media 
was changed after 24 hours, and harvested for total RNA isolation and western blotting (2 wells for 
WB and 1 well for RNA) 48 hours after transfection start.  
Harvesting cells 
Cells were harvested for both RNA-isolation and Western blotting. Cells were typically harvested 
from a 6-well plate, where 3 wells contained cells transfected with scramble siRNA, and 3 wells 
contained cells transfected with PAX6 siRNA. For each transfection, 2 wells were harvested for 
SDS-PAGE and 1 well harvested for RNA-isolation. To wells harvested for SDS-PAGE, 100 µl of 
LDS sample buffer (see materials) per ~300.000 cells were added, scraped and transferred to a 1.5 
ml eppendorf-tube, denatured at 85º C for 5 minutes and stored at -20º C. To cells harvested for 
RNA-isolation, 345 µl Buffer RLT+10 µl Sample Reducing Agent were mixed before added to 
each well. The cells were scraped, transferred to a 1.5 ml eppendorf-tube and stored at -70º C 
pending RNA-isolation. 
Total RNA isolation 
Total RNA was isolated using the RNeasy Mini Kit® from Qiagen
TM
. The method combines 
guanidine-isothiocyanate lysis and a RNA-binding silica membrane spin column. For detailed 
description see manufacturers protocol. In brief, the homogenized cell lysate (cells harvested for 
RNA-isolation) is transferred to a gDNA (genomic DNA) eliminator spin column and centrifuged 
for 30 seconds at 11000 rpm. 70% ethanol is added to the flow-through to enhance binding 
properties. The sample is then transferred to an RNeasy spin column and centrifuged for 15 seconds 
at 11000 rpm. The flow-through is discarded and the spin column washed 3 times in washing buffer 
according to the manufacturer’s instruction manual. The total RNA is eluted in 30 µl RNase-free 










. Before loading the sample, a reference was loaded to ―blank‖ the 
instrument. The total RNA was eluted in water, so water was used as the reference in this study. 1 
µl sample was applied for each measurement, and the concentration was reported in µg/ml. The 
ratio between wavelengths 260/280 and wavelengths 260/230 gave an indication on the quality of 




The total RNA from the RNA isolation was reverse transcribed into its complementary DNA strand 
(cDNA) by using the SuperScript
®
III Reverse Transcriptase kit from Invitrogen
TM
. The cDNA was 
reverse transcribed using random hexamer primers. The cDNA synthesis was performed in 2 steps: 
 cDNA synthesis – Step 1 
 1 µg Total RNA 
 20 µM Random hexamer primers 
 1 µM dNTP mix 
 Water up to 26 µl 
 
The samples were incubated at 65º C for 5 minutes and then moved on ice for >5 minutes. 
 
 cDNA synthesis – Step 2 
 8 µl 5X First-Strand buffer  
 2 µl 0.1 M DTT 
 2 µl RNaseOUT
®
 




The samples were incubated at 25º C for 5 minutes and the moved to 50º C for 1 hour. The reaction 
was inactivated by heating to 70º C for 15 minutes, moved on ice and finally the newly synthesised 




Quantitative real-time PCR (qPCR) 
The quantitative real-time PCR is, in contrast to traditional end-point PCR, both quantitative and 
qualitative. The principle of qPCR is the same as for traditional PCR, but the amplified sequence is 
detected in real-time, between each cycle, instead of analysing the product only at the end of the 
PCR-reaction. 
In this study the Briliant II SYBR
®
Green QPCR Master Mix from Agilent Technologies
TM
 was 
used in accordance with the manufacturer’s instructions. 
 
Figure 3: The mechanism for the SYBRGreen dye. During denaturation (1) the dye is not bound to any double strand DNA, 
and hence the fluorescence is reduced. During annealing (2) and elongation (3), the dye binds to the newly synthesized double 
stranded DNA, and at this point the fluorescent signal is measured. 
(Source: http://upload.wikimedia.org/wikipedia/commons/6/6b/PCR_with_SYBR_green.jpg) 
For the qPCR reaction a 96-well plate was used, with a total of 25 µl of reaction mix in each well. 
For each primer-pair, two technical replicates were made to evade variation. For each plate, a ―no 
template control‖ (NTC) and a ―no reverse transcriptase‖ (no RT) control were ran. The NTC was 
the qPCR reagents with template (cDNA) replaced with water, and the no RT control was a 
prepared product of RNA-to-cDNA reaction ran without reverse transcriptase. The NTC was added 
to ensure no contamination of the reagents with DNA, and the no RT control was to ensure absence 




Table 10: qPCR reaction mix (1 sample) 
Component Quantity 
SYBR®Green master mix 12.5 µl 
Water 9.5 µl 
Forward primer (10 µM) 1 µl 
Reverse primer (10 µM) 1 µl 
Template (diluted cDNA) 2 µl 
Total 25 µl 
 
The qPCR reaction was run on a Stratagene Mx3000P
®
 QPCR System from Agilent 
Technologies
TM
, and the raw data was analysed on the MxPro
TM
 QPCR software. 
Table 11: Thermal cycler profile 
Step Temperature Time Cycles 
Denaturation 95 º C 10 min 1 
Denaturation 95 º C 15 sec 
45 
Annealing/elongation 60 º C 60 sec 
 
The instrument was set to run 45 cycles, but all CT (cycle threshold) values greater than 37 was 
considered as not detected due to the indicative of minimal amount of target sequences present in 
the sample. Technical replicates with a ΔCT of more than 1 were also rejected. The CT-value for 
each reaction was automatically set by the software, and the amplification curve for each reaction 
was controlled to have reached log phase. Relative gene expression (fold change) was determined 
by using the 2
-ΔΔC
T calculation method [43]. To study the relative gene expression, and not do 
absolute quantification, is preferable in the sense that we wanted only to study the difference in 
gene expression between a control sample (SCR siRNA) and a PAX6 knock-down sample (PAX6 
siRNA). SYBR green was used in the PCR chemistry. SYBR green is much more cost-efficient 
than TaqMan probes, and for comparative real-time PCR it provides acceptable results. Melting 
curves were studied to make sure only one product was amplified, and random PCR-product were 





Primers were designed using the free software AmpliFx 1.6.1. Primers were designed so that the 
amplicon would cross intron-exon boundaries. This was done to allow easy detection of 
amplification of genomic DNA if significant genomic contamination occurred. The primers were in 
addition designed so that the amplicon would be no longer than 150 pb. The purpose of this was to 
minimize potential effects of degradation of mRNA. For some genes where the genomic maps 
indicated existence of several transcripts, we designed two primer sets: one to detect exclusively the 
full length transcript, and one to detect most or all existing transcripts (when possible). 
SDS-PAGE 
Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis (SDS-PAGE) is method used to 
separate proteins based on their molecular mass. SDS is an anionic detergent that denatures the 
proteins, and gives the proteins a negative charge that is evenly distributed relative to the proteins’ 
mass. This distribution of charge results in the size fractionation during the electrophoresis. In this 
study, the PowerEase® 500 Power Supply and the XCell SureLock™ Mini-Cell systems from 
Invitrogen™ were used. There are different types of gels on the marked, and in this study the 
NuPAGE® Bis-Tris gels with a 4-12% gradient from Invitrogen
TM
 was used for the SDS-PAGE. 
Harvested cell-lysates for SDS-PAGE were loaded (18-25 µl) to the gel, and the gel was run for 40 
minutes with a constant current of 200 V. The gel was then immediately prepared for western blot. 
Western Blot 
Western blotting is a method used to detect specific proteins/peptides in a complex mixture of 
proteins. The proteins that have been separated during the SDS-PAGE can be analysed with western 
blot. Proteins are transferred from the gel with an electric current to a nitrocellulose membrane 
where they are immobilized. The proteins can then be detected by using antibodies that target the 
proteins of interest, followed by secondary antibodies containing an infra read dye that targets the 
primary antibodies. In this study, the XCell II™ Blot Module from Invitrogen™ was used to 
perform the western blot. The membrane was developed in an Odyssey
® 
SA instrument from LI-
COR
®
. Western blots were performed to identify the presence and, relatively, the quantity of 
various proteins. 
We used typically NuPAGE® Novex® 4-12% Bis-Tris Gels with thickness of 1.0 mm - 12 wells 
each. Before loading into the gel, protein samples were sonicated on ice until viscosity dropped do 
acceptable levels. The samples were briefly vortexed and briefly spinned down. Electrophoresis was 
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run according to the manufacturer’s instructions, usually for 50 minutes. We were adding 
NuPAGE® Antioxidant reagent (500 ul) into the inner chamber of the electrophoresis system 
immediately before applying the electric current. 
The gel was mounted with a nitrocellulose membrane in the Blot Module, and the module was filled 
with blotting buffer. The Blot Module was checked for leakage, and placed in the Mini-Cell. The 
Mini-Cell was then filled 2/3-full with blotting buffer. The blot ran for 2 hours with a constant 
current of 150 V. The membrane was then rinsed in deionized water and allowed to dry before 
placed in a 50 ml falcon tube containing 5 ml blocking buffer. The falcon tube was put on a rotator 
for 1 hour. Primary antibody was diluted to preferred concentration in blocking buffer, and 3 ml 
were added to the falcon tube after the initial blocking buffer had been thoroughly removed. The 
membrane was incubated with the primary antibody on a rotator for 2 hours (sometimes overnight 
at 4º C), before washed 5×5 minutes with 5 ml TBST. Secondary antibody was diluted 1:10000 in 
blocking buffer and added to the membrane. The membrane was protected from light and incubated 
with the secondary antibody on a rotator for 1 hour, and then washed 5×5 minutes with 5 ml TBST, 
followed by a final rinse with TBS. The falcon tube containing the membrane was then filled with 
TBS, protected from light and brought to the Odyssey
®
 SA instrument for development. The 
membrane was stored in deionized water, protected from light at 4º C. 
 
Real-time monitoring of cells - xCELLigence® 
To study the effects on PAX6 siRNA transfected cells in real-time, the xCELLigence® system from 
Roche® was used. The xCELLigence system allows for label-free and dynamic monitoring of 
cellular phenotypic changes in real time using impedance as readout. The system measures 
electrical impedance across coupled gold micro-electrodes integrated on the bottom of tissue culture 
plates. The impedance measurement, which is displayed as cell index (CI) value, provides 
quantitative information about the biological status of the cells, including cell number, viability and 
morphology. In this study we used E-plates and CIM-plates to study proliferation and migration, 
respectively. 
E-Plate 
On the E-plate, each individual well incorporates a sensor electrode array that allows cells in the 
well to be monitored. Each plate contains 16 wells. In the presence of cells, cells attached to the 
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electrode sensor surfaces act as insulators and thereby alter the local ion environment at the 
electrode-solution interface, leading to increased impedance. The more cells that grow on the 
electrodes, the larger the value (CI) gets. 
Before cells were seeded into the E-plate, 60 µl of media was added to each well. The plate was 
then placed in the instrument, and the baseline impedance was registered. Then 100 µl of cell 
suspension containing the desired amount of cells were seeded into each well. The plate was left 1 
hour outside the instrument allowing cells to precipitate before measurements could start. The CI 
was recorded each 15 minute for the first 24 hours, and then each 30 minutes for the rest of the run. 
CIM-Plate 
In this study, the CIM-plate was used to study cell migration assays on the xCELLigence® RTCA 
DP instrument. The CIM-Plate contains 16 wells which comprises an upper chamber and a lower 
chamber. The upper chamber has 16 wells that are sealed at the bottom with a microporous 
polyethylene terephthalate (PET) membrane containing microfabricated gold electrode arrays on the 
bottom side of the membrane. The 16 wells of the lower chamber serve as a reservoir for media and 
any chemoattractant. 
Prior to being transferred into CIM-plates, cells were serum-starved for 24 hours. Cells were seeded 
in desired amount in the upper chamber of the CIM-plate. The bottom chambers of the CIM-plates 
were filled with serum-containing media (to promote migration across membranes towards the 
serum gradient), or serum-free media. The CIM-plate was then transferred into the xCelligence for 
continuous read-outs. Impedance (Cell Index) was registered only from cells capable of migrating 
through the porous membrane. 
 
Real-time monitoring of cells – IncuCyte® 
The IncuCyte® ZOOM instrument from Essen BioScience® allows for live content imaging. In 
short, this means the acquisition, analysis and quantification of images from live cells that remain 
unperturbed by the detection method, allowing for repeated measures over longer periods of time. 
The instrument consists of an imaging module placed inside a standard 37º C 5% CO2 incubator, 
and a powerful data processing unit. The instrument can hold both different types of plates and 
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different types and sizes of flasks. It can take images in HD phase-contrast, and detect green and red 
fluorescence. 
For this thesis, proliferation studies, migration studies and apoptosis studies were performed on the 
IncuCyte® ZOOM. 96 well plates were used to study both proliferation and migration. For the 
proliferation study, 3000-5000 cells per well (depending on cell line), were seeded into a 96 well 
plate. The plate was placed in the IncuCyte, and the instrument was typically programmed to take 
two pictures per well with one hour intervals. The proliferation rate was calculated by the 
instrument software and presented as graphs. For the migration study, 30000-40000 cells per well 
(depending on cell line), were seeded into a 96 well plate, and placed in a 37º C 5% CO2 incubator. 
When cells had attached, a scratch wound was made in each well by using a specialized device 
provided from the manufacturer. After the wounding, the wells were washed two times with PBS to 
remove cell debris derived from the wounding. The plate was placed in the IncuCyte, and the 
instrument was programmed to take two pictures per well with one hour intervals. The migration 
rate into the wound was calculated by the instrument software and presented as graphs. The 
apoptosis rate was analysed from the same cells as the proliferation study by adding the Essen 
CellPlayer™ Caspase-3/7 apoptosis reagent from BioScience®. Stimulation of either the extrinsic 
or intrinsic apoptotic pathways triggers a signalling cascade that results in the activation of 
caspases, which in turn cleave substrates following an Asp amino acid residue. When the Caspase-
3/7 apoptosis reagent is added to the cell culture growth medium, this inert, non-fluorescent 
substrate freely crosses the cell membrane where it is cleaved by activated caspase-3/7 resulting in 
the release of the DNA dye and green fluorescent labelling of DNA, which can be measured by the 








ICW is a technique for quantification of intracellular signalling in whole cells. Cells are seeded into 
96 well plates and target-specific primary antibodies and infrared-labelled secondary antibodies are 
used to detect target proteins in fixed and cells. The 96 well plates were analysed on the Odyssey
® 
SA instrument from LI-COR
®.
 
Cells are grown close to confluence in a 96 well plate before media is removed and 150 µl fixation 
solution containing 3.7% formaldehyde in 1X PBS is added to each well. The plate is incubated for 
20 minutes before fixation solution is removed. The cells were permeabilized by washing 5×5 
minutes on a rotator in 200 µl Triton washing solution containing 0.1% Triton X-100 in 1X PBS. 
After the last wash, 150 µl blocking buffer is added, and the plate is incubated for 1.5 hours with 
moderate shaking. Blocking buffer is then removed and 50 µl of primary antibody diluted in 
blocking buffer is added to each well. Cells and primary antibody is incubated overnight at 4º C 
with gentle shaking. Primary antibody is removed and cells are washed in 200 µl 1X PBS 
containing 0.1% Tween-20 for 5×5 minutes on a rotator. After the last wash, 50 µl of secondary 
antibody diluted in blocking buffer is added to each well, and the plate is incubated protected from 
light for 1 hour on a rotator. Cells are then again washed in 200 µl 1X PBS containing 0.1% Tween-
20 for 5×5 minutes on a rotator. After the last wash, the PBS is thoroughly removed and the plat is 
protected from light and brought to the Odyssey
®
 SA instrument for imaging. The plate is stored 





The main goal of this thesis was to study the molecular and phenotypic effects of the transcription 
factor PAX6 in lung cancer cell lines. Knock-down of PAX6 expression was achieved by 
transfecting PAX6 siRNA into cells. Genes and proteins of interest were studied using real-time 
qPCR and western blotting, respectively. The significance of PAX6 for cells’ ability to proliferate, 
migrate and undergo/evade apoptosis was studied using two systems for real-time monitoring of 
cells in culture. 
Transfection of PAX6 siRNA and SCR siRNA 
The lung cancer cell lines NCI-H460 and NCI-H661 were transfected with PAX6 siRNA and 
scrambled (SCR) siRNA in this study. To determine the efficiency of the transfection, a plasmid 
encoding Green Fluorescent Protein (GFP) was co-transfected in the initial transfections. Cells 
would emit green fluorescence if plasmids encoding the GFP had been successfully transfected and 
the protein was expressed. Amount cells expressing green fluorescence compared to the amount of 
non-expressing cells, gave an estimate of the overall transfection efficiency. Figure 4 show PAX6 
siRNA and SCR siRNA transfected cells, co-transfected with GFP. The field of view is the same in 
the brightfield photo as for the fluorescence photo. This allows for direct comparison between the 
two pictures. 
Figure 4: Co-transfection of a plasmid encoding the GFP was used to determine the transfection efficiency. 






As figure 4 shows, most cells emit green signal. The fluorescence signal is somewhat weaker in the 
H460 cells compared with the H661 cells, which is probably due to the fact that these cells are 
smaller, and thus the transfected amount will be less. The transfection efficiency is >70% for both 




Real-Time PCR (qPCR) 
To study potential regulation of putative and known target genes, qPCR was performed on a number of 
genes selected for their association with cancer. For each cell line, a minimum of three biological 
replicates were analysed. In accordance to the 2-ΔΔCT calculation method, a fold change of 1 (or -1) is 
equal to no regulation of the target gene [43]. An average fold change <1≥0≤-1 indicates significant 
variations between biological replicates, and is not considered valid data. The results from the qPCR are 
presented in table 9 and table 10 for the cell lines NCI-H661 and NCI-H460, respectively. 
Table 12: qPCR results for selected genes in H661 cells transfected with PAX6 siRNA. Values for PAX6 indicate level of 
knock-down in cells transfected with PAX6 siRNA. Genes highlighted in green show similar regulation patterns between three to 
four biological replicates. 
 
Fold change   Statistics 
 Gene Exp.1 Exp.2 Exp.3 Exp.4 
 
Average SD CV (%) Range Regulation 
AKT3-1 1.1 -1.1 1.4 1.2 
 
0.6 1.2 187.2 2.5   
AKT3-2 1.1 -1.1 1.4 1.4 
 
0.7 1.2 165.2 2.5   
ANG1 -1.1 1.1 1.4 -1.1 
 
0.1 1.4 1974.2 2.5   
CTGF-1 1.7 1.2 2.1 1.5 
 
1.6 0.4 23.7 0.9 Downregulated by PAX6 
CTGF-3 1.5 1.1 1.9 1.4 
 
1.4 0.3 22.8 0.8 Downregulated by PAX6 
DKK3 1.4 1.3 1.3 1.4 
 
1.3 0.1 4.6 0.1 Downregulated by PAX6 
P53 -2.1 - -1.4 -1.0 
 
-1.5 0.4 28.8 1.1 Upregulated by PAX6 
PAX6 -10.0 -15.1 -5.9 -4.6 
 
-8.9 4.7 53.3 10.5   
PDGFB -1.1 -1.0 1.2 1.5 
 
0.2 1.4 896.6 2.5   
PTEN -1.7 -1.8 -1.4 -1.4 
 
-1.6 0.2 13.9 0.5 Upregulated by PAX6 
TF1 - 1.1 1.9 1.8 
 
1.6 0.4 26.7 0.8 Downregulated by PAX6 
TFPI1 -1.2 -1.1 1.0 1.0 
 
-0.1 1.3 2012.0 2.2   
TGFB1 1.5 1.1 1.4 1.3 
 
1.3 0.2 12.5 0.4 Downregulated by PAX6 
TGFBI -1.2 1.1 -1.6 -1.2 
 
-0.7 1.2 173.9 2.7   
VEGFA -1.3 -1.1 1.5 1.0 
 
0.0 1.4 4610.8 2.8   
VEGFC -1.9 -1.0 -1.0 1.1 
 
-0.7 1.3 178.5 3.0   
VEGFD -3.2 -2.6 -1.9 -2.2 
 
-2.4 0.6 23.1 1.3 Upregulated by PAX6 
VEGFR1 -1.0 -1.3 -1.2 -1.6 
 
-1.3 0.2 17.4 0.5 Upregulated by PAX6 
VEGFR2 -1.2 -1.3 1.3 -1.2 
 
-0.6 1.3 213.8 2.6   
VEGFR3 - 1.3 1.5 1.4 
 
1.4 0.1 6.2 0.2 Downregulated by PAX6 
BMP2 1.1 -1.0 1.2 - 
 
0.4 1.3 294.0 2.2   
EIF4H-1 -1.7 -1.9 -2.4 - 
 
-2.0 0.3 16.4 0.6 Upregulated by PAX6 
EIF4H-2 -1.7 -1.0 -1.4 - 
 
-1.4 0.3 22.9 0.6 Upregulated by PAX6 
SFRP1 1.3 -1.2 -1.4 - 
 
-0.4 1.5 339.3 2.7   
SFRP2 -1.9 -2.0 -2.2 - 
 
-2.0 0.1 5.5 0.2 Upregulated by PAX6 
v-MYC 1.6 1.5 1.4 - 
 
1.5 0.1 8.8 0.3 Downregulated by PAX6 
WNT2b-1 -2.2 -1.4 1.3 - 
 
-0.8 1.8 237.3 3.5   
WNT2b-2 1.6 -1.2 1.5 - 
 
0.7 1.6 242.9 2.8   
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Table 13: qPCR results for selected genes in H460 cells transfected with PAX6 siRNA. Values for PAX6 indicate level of 
knock-down in cells transfected with PAX6 siRNA. Genes highlighted in green show similar regulation patterns between three to 
four biological replicates. 
 
Fold change   Statistics 
 Gene Exp.1 Exp.2 Exp.3 Exp.4 Exp.5 
 
Average SD CV (%) Range Regulation 
AKT3-1 1.1 1.3 1.1 1.2 1.1 
 
1.2 0.1 8.5 0.3   
AKT3-2 1.2 1.3 1.3 1.0 1.1 
 
1.2 0.1 11.6 0.3   
ANG1 1.3 1.4 1.5 -1.1 -1.5 
 
0.3 1.5 455.1 3.0   
CAV1 1.6 1.6 - 1.3 1.0 
 
1.4 0.3 19.2 0.6 Downregulated by PAX6 
CTGF-1 1.0 1.0 -1.4 -1.3 1.5 
 
0.2 1.4 787.1 2.9   
CTGF-3 1.0 1.0 1.1 -1.1 1.8 
 
0.8 1.1 143.0 2.9   
DKK3 1.5 2.9 - -1.0 -1.1 
 
0.6 2.0 342.4 4.0   
P53 1.8 1.7 3.5 -1.61 1.3 
 
1.4 1.9 137.5 5.1 Downregulated by PAX6 
PAX6 -1.9 -2.0 -5.1 -2.9 -6.4 
 
-3.6 2.0 54.9 4.5   
PDGFB -1.0 -1.2 -1.0 - - 
 
-1.1 0.1 10.6 0.0   
PTEN -1.0 -1.4 -1.3 1.1 -1.0 
 
-0.7 1.0 140.6 2.5   
TF1 1.6 1.3 - 1.1 -1.1 
 
0.7 1.2 174.6 2.7   
TFPI1 1.1 1.1 - -1.3 -1.2 
 
-0.1 1.3 1502.5 2.4   
TGFB1 1.0 1.2 1.5 1.1 1.2 
 
1.2 0.2 13.0 0.4   
TGFBI 1.2 1.1 -1.3 1.0 1.1 
 
0.6 1.1 167.8 2.4   
TNFa -1.5 -1.0 - 1.2 - 
 
-0.4 1.5 330.9 2.8   
VEGFA 1.0 1.3 -1.4 1.1 1.3 
 
0.7 1.2 175.8 2.7   
VEGFC -1.3 1.1 -1.5 -1.0 1.4 
 
-0.3 1.4 514.0 2.8   
VEGFD 1.3 1.2 -1.1 1.1 1.5 
 
0.8 1.1 134.0 2.6   
VEGFR1 -1.0 -1.8 1.7 - - 
 
-0.4 1.9 478.4 3.6   
VEGFR2 -1.4 -1.1 -1.9 -1.1 -2.3 
 
-1.6 0.5 33.7 1.2 Upregulated by PAX6 
VEGFR3 1.1 1.7 1.3 - 1.9 
 
1.5 0.3 23.0 0.8 Downregulated by PAX6 
BMP2 - - -2.7 -1.1 1.1 
 
-0.9 1.9 207.0 3.8   
BTC - - -1.4 1.4 1.1 
 
0.4 1.6 421.8 2.8   
MAX-1 - - 1.3 1.3 -1.2 
 
0.5 1.4 301.0 2.5   
MAX-2 - - 1.4 -1.0 -1.3 
 
-0.3 1.5 477.0 2.7   
MXD-1 - - -2.0 -1.1 -1.5 
 
-1.5 0.4 27.5 0.8 Upregulated by PAX6 
v-MYC - - -1.4 1.1 -1.2 
 
-0.5 1.4 298.7 2.5   
WNT2b-1 - - 1.7 1.6 2.0 
 
1.8 0.2 13.1 0.5 Downregulated by PAX6 
WNT2b-2 - - 1.5 1.6 1.0 
 
1.4 0.3 21.1 0.5 Downregulated by PAX6 
 
  
                                              
1 This value is not in accordance with the other biological replicates for P53, hence the large SD and CV compared with 
other genes of interest (marked in green). P53 is still, however, considered a possible target for regulation due to the fact 
that 4 out of 5 biological replicates indicate regulation in the same direction. 
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The results from the qPCR imply that several genes may be regulated, directly or indirectly, by the 
transcriptions factor PAX6. Table 11 and 12 lists these potential genes with a short description of 
their function/association. 
 
Table 14: Genes that show regulation by PAX6 in the cell line H661. 
 
Fold change   Statistics 
  Gene Exp.1 Exp.2 Exp.3 Exp.4 
 
Average SD CV (%) Range Regulation Function 
CTGF 1.7 1.2 2.1 1.5 
 





DKK3 1.4 1.3 1.3 1.4 
 
1.3 0.1 4.6 0.1 Downregulated by PAX6 Wnt signalling (-) 
PAX6 -10.0 -15.1 -5.9 -4.6 
 
-8.9 4.7 53.3 10.5     
TGFB1 1.5 1.1 1.4 1.3 
 
1.3 0.2 12.5 0.4 Downregulated by PAX6 Growth factor 
VEGFD -3.2 -2.6 -1.9 -2.2 
 
-2.4 0.6 23.1 1.3 Upregulated by PAX6 Angiogenesis 
PTEN -1.7 -1.8 -1.4 -1.4  -1.6 0.2 13.9 0.5 Upregulated by PAX6 Tumor suppressor 
VEGFR1 -1.0 -1.3 -1.2 -1.6 
 
-1.3 0.2 17.4 0.5 Upregulated by PAX6 Angiogenesis 
VEGFR3 - 1.3 1.5 1.4 
 
1.4 0.1 6.2 0.2 Downregulated by PAX6 Angiogenesis 
EIF4H-1 -1.7 -1.9 -2.4 - 
 
-2.0 0.3 16.4 0.6 Upregulated by PAX6 Initiation factor 
EIF4H-2 -1.7 -1.0 -1.4 - 
 
-1.4 0.3 22.9 0.6 Upregulated by PAX6 Initiation factor 
SFRP2 -1.9 -2.0 -2.2 - 
 
-2.0 0.1 5.5 0.2 Upregulated by PAX6 Wnt signalling (-) 
v-MYC 1.6 1.5 1.4 - 
 
1.5 0.1 8.8 0.3 Downregulated by PAX6 TF/Oncogene 
 
 
Table 15: Genes that show regulation by PAX6 in the cell line H460. 
 
Fold change   Statistics 
  Gene Exp.1 Exp.2 Exp.3 Exp.4 Exp.5 
 
Average SD CV (%) Range Regulation Function 
CAV1 1.6 1.6 - 1.3 1.0 
 
1.4 0.3 19.2 0.6 Downregulated by PAX6 Tumor suppressor 
P53 1.8 1.7 3.5 -1.6 1.3 
 
1.4 1.9 137.5 5.1 Downregulated by PAX6 Tumor suppressor 
PAX6 -1.9 -2.0 -5.1 -2.9 -6.4 
 
-3.6 2.0 54.9 4.5     
VEGFR2 -1.4 -1.1 -1.9 -1.1 -2.3 
 
-1.6 0.5 33.7 1.2 Upregulated by PAX6 Angiogenesis 
VEGFR3 1.1 1.7 1.3 - 1.9 
 
1.5 0.3 23.0 0.8 Downregulated by PAX6 Angiogenesis 
WNT2b - - 1.7 1.6 2.0 
 






Genes that showed potential regulation by use of qPCR were next analysed on western blots for 
visualisation of changes in protein level. For most of the target genes, however, antibodies against 
the corresponding proteins were not available or had bad quality, which left the following set of 








DKK3 appears to be upregulated in the PAX6 knock-down sample (figure 6). This correlates well 
with the data from the qPCR analysis for H661, which suggests that gene expression of DKK3 is 








The knock-down of PAX6 seem, in a very subtle way, to 
down regulate the expression of ANG3 (figure 8). 
Because this difference is so miniscule, caution should be 
taken in interpreting these results. CTGF appears to be 
downregulated for both cell lines by the presence of 
PAX6 
ACTIN 
40 kD  
50 kD  
60 kD  
Figure 5: PAX6 + ACTIN. Both cell lines 
show knock-down of PAX6 on protein level. 
PAX6 
ACTIN 40 kD  
50 kD  
60 kD  
Figure 7: 20120514A: PAX6 + ACTIN. 
Knock-down of PAX6 is evident in both 
cell lines. 
ANG3 
50 kD  
60 kD  
Figure 8: 20120514A: ANG3. The knock-down 
of PAX6 may seem to down regulate ANG3, but 
the difference is very subtle. 
ACTIN 
CTGF 
30 kD  
40 kD  
Figure 9: 20120514B: CTGF. The knock-
down of PAX6 results in an up regulation of 




50 kD  
60 kD  
80 kD  
Figure 6: DKK3. The knock-down of PAX6 
results in an up regulation of DKK3 in both 
H460 and H661. Around 70 kD there are 




PAX6 (figure 9). This is in accordance with the H661 data from the qPCR, which suggests that 
gene expression of CTGF is downregulated by PAX6 (table 14). The downregulation of CTGF by 
PAX6 is opposite of what is reported in a recent study (Kiselev et al., 2012). 
 
 
The blot in figure 11 shows the same down 
regulation of CTGF by PAX6 as the blot in 
figure 9, again confirming the qPCR results for the H661 cell line. In the H460 cell line (figure 11), 
the CTGF protein is suspected of beeing subject for post-translational modification 
(glycosylation?), resulting in a protein with a molecular weight of 65 kD. This modification was 
not, however, observed in the experiment represented in figure 9. This will be discussed later. 
  
PAX6 
40 kD  
50 kD  
60 kD  
Figure 10: 20120529A: PAX6. Both cell lines 
show knock-down of PAX6 on protein level. 
40 kD  ACTIN 
CTGF 
30 kD  
CTGF 65 kD ? 
40 kD  
50 kD  
60 kD  
Figure 11: 20120529A: CTGF. The knock-down 
of PAX6 results in an up regulation of CTGF in 
both cell lines. The CTGF protein in the H460 cell 
line is suspected to be heavily glycosylated, hence 
its increased molecular weight. Binding between 
40kD and 50kD are leftovers from PAX6 antibody 
from figure 10. 
40 kD  ACTIN 
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Real-time monitoring of cells - xCELLigence® 
The lung cancer cell lines H460 and H661 ability to proliferate and migrate after the knock-down of 
PAX6, was assessed in real-time using the xCELLigence system from Roche. For the proliferation 
study, typically 3000-4000 cells were seeded in each well in an E-plate. For the migration study, 
40000-50000 cells were seeded in each well in a CIM-plate. The plates were mounted in the 
instrument, and the impedance (cell index) was set to be measured every 15 minute for the first 3 
hours, and then every 30 minute for the rest of the run, which varied between 30 hours and 150 
hours. The results are presented as graphs showing cell index on the x-axis and time in hours on the 
y-axis. 
Proliferation study 
The proliferation study was performed in a 16-well E-plate. 
The graphs show the proliferation rate, with 
the time (in hours) on the x-axis and the cell 
index on the y-axis. One should be aware of 
that, to provide optimal visualisation, the 
four graphs (figure 12 and 13) do not have 
the same scaling on either axis. For the 
experiments presented in figure 15 and 
figure 17 the same trend is observed - that 
PAX6 seems to have a positive effect on 
proliferation. For the experiment in figure 
20, media was changed after ~20 hours. 
This caused a disturbance in the cell index, 
and the graphs were normalized at ~24 
hours to compensate for this. 
  
Figure 12: Proliferation study. PAX6 promotes proliferation in H460. 
SCRsi 
PAX6si 





Figure 14 shows the proliferation rate 
for the only experiment with the H661 
cell line that gave any plausible results. 
Media was changed after ~20 hours, 
which caused a major disturbance in 
cell index, and the graphs were 
normalized to try and compensate for 
this. The experiment suggests that 
PAX6 has a negative effect on proliferation in the H661 lung cancer cell line. The cells transfected 
with SCR siRNA show indication of cell death after media change, and only has a slight indication 
of regained proliferation after ~50 hours. 
Migration study 
The migration study was performed in a 16-well 
CIM-plate as described in materials and methods. 
Cells were seeded in 6-well dishes, transfected 
for four hours, grown for 48 hours (including the 
serum starvation period), harvested and seeded in 
the CIM-plate. 
The graphs show the migration rate, with the time 
(hours) on the x-axis and the cell index on the y-
axis. One should be aware that the three graphs 
(figure 15-17) do not have the same scaling on 
either axis. Figure 15 and figure 16 show the 
results from experiments with the H661 cell line, 
and figure 17 the results from the H460 cell line. 
All three experiments suggest that PAX6 is 
inhibiting migration of these cell lines. For the 
H661 cell line the migration is apparent 
approximately 50 hours earlier then for the H460 
cell line. The purple and blue graphs in figure 17 
represents PAX6si and SCRsi transfected cells, 
PAX6si 
SCRs
Figure 16: Migration study. PAX6 inhibits migration in H661. 
PAX6si 
SCRsi 
Figure 15: Migration study. PAX6 inhibits migration in H661. 
SCRsi 
PAX6si 
Figure 17: Migration study. PAX6 inhibits migration in H460. 
Purple and blue graphs show PAX6si and SCRsi transfected cells, 
respectively, with serum free media in lower chamber. 
PAX6si 
SCRsi 
Figure 14: Proliferation study. PAX6 inhibits proliferation in H661. 
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respectively, with serum free media in the lower chambers. This indicates that neither PAX6si 
transfected nor SCRsi transfected cells will migrate without serum as an attractant in the lower 
chamber.  
Real-time monitoring of cells – IncuCyte® 
The lung cancer cell lines H460 and H661 ability to proliferate and migrate was also studied in the 
IncuCyte® ZOOM instrument from Essen BioScience. Apoptosis was also monitored, using the 
Kinetic Caspase-3/7 Apoptosis Assay from Essen BioScience. Cells were seeded in 96-well plates. 
For the proliferation study and apoptosis study, typically 4000 cells were seeded in each well, and 
for the migration study, 30000 cells were seeded in each well. For all studies, the instrument was 
programmed to take two pictures from each well every hour. 
Proliferation study 
Cells were seeded in the wells, allowed 
to attach to the well surface, transfected 
for four hours, and placed in the 
instrument for real-time monitoring. 
For this method, proliferation results are 
only available for experiments done with 
the H460 cell line. Several other siRNAs 
were studied on the same plate, hence the 
many graphs, but these will not be 
addressed in this thesis. In both 
experiments (figure 18 and 19), PAX6 
appears to have a positive effect on 
proliferation. This is the same trend as 
observed for the xCelligence experiments 
presented in figure 12 and 13. 
  
Figure 19: Proliferation study. PAX6 promotes proliferation of H460. 
PAX6si 
SCRsi 






The migration study was performed in a 96-well plate. Cells were seeded in 96-well plates, 
transfected for four hours and placed in the instrument. Cells were allowed to grow close to 
confluent before a scratch wound was made as described in materials and methods. 
For the migration study, only 
one result from NCI-H661 
has been obtained due to very 
limited availability of the 
instrument. No results from 
the NCI-H460 cell line was 
obtained for this method. The 
results from the migration 
study (figure 20) indicate that 
PAX6 might have a negative 
effect on migration. This is 
the same trend as is observed 
for the real-time monitoring using the xCellingence system. 
  
SCRsi 





The apoptosis study was performed in a 96-well plate. Cells were seeded in 96-well plates, 
transfected for four hours before media was changed and the Caspase-3/7 reagent added. The plate 
was placed in the instrument and two fluorescence pictures per well was taken every hour. 
For the apoptosis study 
(figure 21 and 22), one 
experiment for each cell line 
was performed. In the 
presence of apoptosis, caspase 
will react with the Caspase-
3/7 reagent and emit green 
florescent signal which is 
detected by the instrument. 
The x-axis show green 
florescent signal-count and 
the y-axis shows time in 
hours. For both cell lines, 
PAX6 appears to protect the 
cells from entering apoptosis. 
For the NCI-H460 cell line, 
the effect is apparent after 
~100 hours, when cells are 
close to confluent. For the 
NCI-H661 cell line the affect 
becomes significant after 
close to 30 hours, when cells 






Figure 21: Apoptosis study. PAX6 protects against apoptosis in H460. 
SCRsi 
PAX6si 




The aim of this thesis was to identify novel cancer-associated target genes for PAX6 by studying 
the effects of the knockdown of PAX6 expression lung cancer cell lines with endogenous PAX6 
expression, as well as to study the possible effect this knockdown have on proliferation, migration 
and apoptosis. Methods used for this purpose were primarily comparative real-time PCR, western 
blotting, and two different methods for real-time monitoring of living cells. 
The cell lines used for this thesis were the lung cancer cell lines NCI-H460 and NCI-H661. The 
NCI-H460 is an adenocarcinoma cell line that originates from the pleural effusion, whiles the NCI-
H661 is a squamous-cell carcinoma cell line derived from a metastatic site (lymph node). Both cell 
lines are from the NSCLC family and both demonstrate endogenous expression of PAX6. These 
two cell lines were both transfected with PAX6 siRNA and SCR (control) siRNA for the purpose of 
studying the effect on PAX6 knockdown. The initially strategy was to also include cell lines not 
showing endogenous expression of PAX6, and to transfect these cells with a plasmids containing 
PAX6 and PAX6(5a). The cell lines intended for this were the non-small cell lung cancer cell lines 
NCI-H520 and NCI-A549, but the low transfection efficiency observed for both these cell lines 
rendered them not suitable. Both PAX6-negative cell lines have previously been successively used 
in transfection experiments, making the nature of the plasmid and/or the chosen transfection 
reagents a likely cause for the unsatisfactory results. It would have been interesting to compare 
endogenous PAX6 expression with exogenous PAX6 expression to obtain an even deeper 
understanding of the effects of PAX6 in lung cancer, and the optimization of PAX6-plasmid 
transfection into PAX6-negative lung cancer cell lines should be a priority in future studies. 
Genes to be studied were selected prior to the initiation of this thesis, and they were pre-chosen on 
the background of previously described cancer associated target genes of PAX6, molecular/clinical 
data on NSCLC and available antibodies. In addition, a number of genes known to have effect on 
angiogenesis were chosen, due to the fact that many non-small cell lung cancers show both 
increased angiogenic activity and increased expression of angiogenic-associated genes. For each 
gene, a primer-pair was designed in a way that the amplicon would overlap exon-intron boundaries. 




The results from the comparative qPCR suggest a number of genes as possible targets for PAX6, 
and these genes are listed in table 14 and 15. Interestingly, only one gene shows regulation in both 
cell lines on mRNA level. The reason for this lack of consistency in the expression signature 
between the two cell lines may be attributed to the fact that the regulatory properties of PAX6 are 
dose-dependent, and hence may not regulate the same set of genes or in the same direction in cell 
lines with different levels of endogenous PAX6 expression. As well, these two cell lines originate 
from very different types of NSCLC tumours, therefore the biomolecular context in them differs 
greatly, providing additional explanation for the observed differences in PAX6-regulated gene sets.  
In general, living cells are highly dynamic and biological system, and in this aspect one should bear 
in mind that PAX6 may not necessarily be the direct regulator of the implicated genes in this study, 
as it may also interact with many of the other pathways. 
The one gene that shows regulation by PAX6 in both cell lines is VEGFR3, and in both cell lines 
this gene appears to be downregulated by PAX6. The VEGFR-proteins are tyrosine kinase receptors 
for the VEGFs, and they are important signalling molecules in angiogenesis. The VEGFD is 
associated with binding to the VEGFR3, and in the H661 cell line this gene appears to be 
upregulated by PAX6. The downregulation of a receptor together with the upregulation of its 
corresponding ligand, presents a paradox. It could be reasonable to speculate that VEGFD is in fact 
not regulated by PAX6, but instead is involved in a negative-feedback pathway, not affected by 
PAX6, to compensate for the loss of VEGFR3. In the H460 cell line, the VEGFR2 is indicated as 
upregulated. VEGFR2 appears to mediate almost all of the known cellular responses to [44], and 
one could also in this case make the speculation that a negative-feedback loop is involved. 
Assuming VEGFR3 is regulated by PAX6, on the basis of it showing regulation in both cell lines, 
VEGFR2 would in the H460 cell line be the gene regulated via negative-feedback. The DKK3 
protein and the SFRP2 protein are both antagonists in the Wnt signalling pathway, and in the H661 
cell line, these genes show opposite regulation patterns. Table 14 and 15 lists the rest of the genes 
with a short description of their cancer-associated function. 
Table 12 and 13 shows there is a large variations in fold-change between biological replicates. Most 
of this variation is probably due to the difficulties presented in producing comparable replicates. 
The transfection efficiency, cell density, cell passage number and the fact that this is a biological 
system, are all factors that potentially contribute to variation. The quality of the isolated RNA is 
46 
 
another factor that could have influence on the qPCR results. All the primer-pairs designed for this 
study produced amplicons not bigger than 150 bp, and because of this the RNA Integrity Number 
(RIN) was not measured. In addition, for the cDNA synthesis, only random hexamer primers were 
used. To have used random hexamer primers together with anchored oligo-dT primers would have 
been optimal. Anchored oligo-dT primers are specifically designed for synthesising long cDNAs 
from mRNAs carrying poly-A tails. Since this primer only anneals to the poly-A tail junction of the 
mRNA template, it eliminates transcription through the poly-A tail, providing more effective cDNA 
synthesis.  These two modifications to the method could have yielded better/more consistent results 
from the qPCR analyses, and in future experiments they should be implemented. An unfortunate 
coincidence for the majority of the studied genes was their low expression on mRNA level. This 
resulted in very late Ct-values, and therefor increasing between-sample variations. 
Western blot 
The result from the western blots confirms knockdown of PAX6 on protein level for both cell lines. 
There are only a limited number of successful blots available due to several reasons. Ideally, one 
would like to show western blots for all the proteins that show regulation on gene-level, but 
unfortunately this was not achieved. Antibodies were not available for many corresponding 
proteins, and several of the antibodies applied yielded unacceptable results. Some antibodies did not 
show any protein affinity, whilst other antibodies showed very high levels of unspecific binding.  
We were able to show regulation on protein level for CTGF and DKK3. As may be observed in 
figure 6, both cell lines show downregulation of DKK3 on protein-level. For the NCI-H661 cell 
line, this correlates with the results from the qPCR, that indicate the downregulation of DKK3 in the 
presence of PAX6. For the NCI-H460 cell line, this does not correlate with the mean fold change 
observed from the qPCR results. However, two out of four biological replicates do indeed show 
downregulation of DKK3 in this cell line, whilst the last two biological replicates show no 
regulation of DKK3. It is reasonable to assume that PAX6 has regulatory capacity over DKK3, 
directly or indirectly, in both cell lines, and that the inconsistent results from the qPCR for the NCI-
NCI-H460 cell line is due to some of the challenges described earlier. Figure 9 show that also 
CTGF is downregulated by PAX6 on protein-level. Again, this correlates with the qPCR results for 
the NCI-H661 cell line, which show downregulation of CTGF on gene-level, but does not correlate 
with the qPCR results from the NCI-H460 cell line, which show no regulation. For this gene, only 
one out of five biological replicates suggests this gene to be downregulated in the NCI-H460 cell 
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line. However, there are additional regulation phenomena happening between transcription and 
translation, therefore qPCR folds can never be directly trusted as indications of protein regulation.  
The CTGF protein has an expected molecular weight of 36-42 kDa, but figure 11 indicate that the 
protein suspected to be CTGF has a molecular weight of 65 kDa in the NCI-H460 cell line. The 
assumption is that this is a highly glycosylated form of the protein, and maybe even a product of 
dimerization. If this is not a post-transcriptional modified form of CTGF, it is an unspecific 
antibody binding to something else that is regulated by PAX6, which is quite unlikely. Because of 
available antibodies, a single experiment was also performed using antibodies against ANG3 (figure 
8). ANG3 was one of the genes that produced very high Ct-values on the qPCR, and therefor had to 
be excluded from the results. There are perhaps a slight indication of that PAX6 upregulates this 
gene, but the difference is miniscule. 
The co-analysis of regulated genes detected by comparative qPCR with its corresponding protein is 
crucial for the validity of such experiments. But as this study has demonstrated, there are potential 
pit-falls which need to be avoided. Good correlation between gene regulation and protein regulation 
for several targets would have provided solid evidence of the true regulatory capacity of PAX6, 
either as a direct regulator or as a mediator in indirect regulation. 
Real-time monitoring of cells 
For this thesis, two different systems where used for the real-time monitoring of cells; the 
xCelligence system and the IncuCyte system. These systems use different approaches in the 
monitoring of cell proliferation and migration, but only the IncuCyte is capable of monitoring cell 
death via apoptosis. 
Both systems seem to indicate that PAX6 promotes proliferation for the NCI-H460 cell line (figure 
12, 13, 23, 24). Only one proliferation experiment is available for the NCI-H661 cell line (figure 
21). This experiment was performed on the xCelligence system, and it appears that PAX6 inhibits 
proliferation in this cell line. When studying the graph, however, it becomes apparent that this was 
not an optimal experiment. A massive drop in cell index after the adding of transfection mix, and 
later, media change, makes the normalization of this experiment unreliably. This, together with the 
fact that this is the only available experiment for this cell line, makes it unreasonable to make any 
conclusions as to the proliferative effects that PAX6 may have on the NCI-H661 cell line. 
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For the migration study, both systems indicate that PAX6 inhibits migration in both NCI-H460 and 
NCI-H661 (figure 15, 16, 17). For the NCI-H460 cell line, only one experiment with the 
xCelligence system is available for the migration study (figure 17), but the design of this 
experiment makes the result highly credible. There are two sets of PAX6 siRNA transfected and 
SCR siRNA transfected cells in this experiment. One set has media containing serum as a chemo 
attractant in the lower chamber, whilst the other set has serum-free media in the lower chamber. 
After approximately 70 hours, PAX6 knockdown cells start to migrate towards the chemo attractant 
(media with serum), whilst the SCR siRNA transfected cells does not migrate towards the media 
containing serum. Both the PAX6 siRNA transfected and the SCR siRNA transfected cells with 
serum-free media in the lower chamber did not migrate. This indicates that in order for the NCI-
H460 cells to migrate, they are dependent on a chemo attractant and decreased levels of PAX6. This 
is not implying that PAX6 is the master regulator of migration for this cell line, but it shows that 
PAX6 is one factor that has clear effect on migration. For the NCI-H661 cell line, two migration 
experiments was analysed on the xCelligence system, and one migration experiment were analysed 
on the IncuCyte system. All three experiments suggest that PAX6 inhibits migration in NCI-H661 
(figure 15, 16, 20). The two systems use a very different approach in the measurement of migration. 
The IncuCyte system measures the migration of cells into a scratch wound, whilst the xCelligence 
system measures chemotaxis-driven migration through a porous membrane. The NCI-H661 cells 
where shown to migrate regardless of PAX6-status in the IncuCyte system, but the presence of 
PAX6 slows down the migration rate. The NCI-H460 cells do not migrate when expressing PAX6, 
and only migrate along the serum gradient when PAX6 expressing is quenched. This could result in 
NCI-H460 cells not migrating under the conditions provided by the IncuCyte, regardless of PAX6-
status, since there is no chemoattractive gradient present in this system. To summarise, we have 
shown that PAX6 regulates NSCLC cell migration, yet this effect varies depending on the cell lines 
biological properties. 
The study of cell death by apoptosis is a feature only available for the IncuCyte system. One 
experiment for each cell line was performed, and for both cell lines the presence of PAX6 appears 
to inhibit apoptosis (figure 21 and 22). For the NCI-H661 cell line, the different rate of apoptosis 
between PAX6 siRNA transfected cells and SCR siRNA transfected cells becomes apparent after 
approximately 30 hours, when cultures are about 50% confluent. For the NCI-H460 cell line, the 
apoptosis has a sudden onset after approximately 100 hours, with cells expressing PAX6 displaying 
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a slower rate of apoptosis. For this cell line, the cell cultures were close to 100% confluent when 
apoptosis was initiated. 
Both the xCelligence and the IncuCyte are powerful systems when it comes to monitoring the 
behaviour of cells in real-time, but personally I the IncuCyte system to be the best. Despite the 
somewhat limitation in regard to the migration study compared with the xCelligence, it is superior 
when it comes to capacity and the numerous possible different applications it possesses.  In 
particular, the system allows use of various dishes and plates, does not require expensive custom-
produced plates with electrodes, making it a flexible and cheap system. Very importantly, a 
researcher can always refer to the camera shots for each and every well, providing perfect control 
over what exactly happens with the cells (morphology changes, apoptosis, infections, etc). Such a 
tight control is impossible in the xCelligence system. Unfortunately, the IncuCyte system was only 
available for a very short period of time during this master degree study, so its potential was not 
fully exploited. 
Relevance of findings 
This study successfully identifies some potential target genes of the transcription factor PAX6 
relevant for non-small cell lung cancer. The experiments involved the lung cancer cell lines NCI-
H460 and NCI-H661. It is clear that PAX6 has regulatory effects on the identified genes, but if 
these genes are regulated directly by PAX6 or via alternative pathways where PAX6 is involved, 
remains unclear. It is difficult to make a clear association between regulated genes and the cellular 
behaviour observed using the real-time monitor systems. In this study, PAX6 downregulates DKK3 
in both cell lines (on protein level). Downregulation of DKK3 has been shown to induce apoptosis 
in lung adenocarcinoma [45], but in this study the effect seems to be the opposite, as cells 
expressing PAX6, and hence has downregulated DKK3 expression, shows a lower degree of 
apoptosis. High expression of CTGF is associated with suppression of cell proliferation and 
signalling transduction in NSCLC [46], and to inhibit metastasis and invasion of human lung 
adenocarcinoma [47]. Our study shows that PAX6 downregulates CTGF (on protein level) in both 
lung cancer cell lines. The results from the migration study imply that PAX6, and hence 
downregulated amount of CTGF, inhibits migration. The proliferation study associate PAX6, and 
hence downregulated amounts of CTGF, with increased proliferation. The latter observation 
supports the findings described in the literature [46]. 
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Several genes associated with positive survival were also identified as targets for PAX6. These 
include upregulation of the well-known tumor suppressor PTEN, downregulation of one of the 
genes encoding a ligand associated with Wnt (WNT2b), downregulation of VEGFR3 (promotes 
angiogenesis) and also upregulation of the Wnt antagonist SFRP2. These discoveries support the 
unpublished results by Kiselev and Busund, which report a positive correlation between PAX6 and 
survival in non-small cell lung cancer patients. 
Even though the fold-changes for many of the regulated genes are modest, it is important to be 
aware of that for many transcriptions factors such as PAX6, or the more famous MYC, rather 
moderate fold changes are usually seen adequate to propose existence of regulatory association. 
There are of course a multitude of possible explanations and alternative regulated pathways that can 
account for the discrepancies observed when comparing results and studies. These are, as stated 
earlier, highly dynamic, biological systems with immense molecular interactions, and to present a 
statement on the basis of variations observed on single events, would be unwise. However, the sets 
of genes which were shown to be regulated by PAX6 in this project have plausible relevance for 
lung cancer biology and may in part provide mechanistical explanation of PAX6’s biological effects 





A lot more research on the transcription factor PAX6 role in non-small cell lung cancer progression 
is necessary to reveal it true role in this type of cancer. The identification of more cancer associated 
target genes is crucial in this aspect. The possibility presented by real-time monitoring of cells, is a 
very valuable tool in studying the biological effects that different genes have in different cell lines. 
The discovery of more target genes together with real-time monitoring of cellular response to 
manipulation of these genes, in several cell lines, should be a priority in future experiments. 
Another very valuable tool would have been the use of a laser micro-dissection method performed 
on formalin fixed paraffin embedded tissue sections. This would have allowed cell collection from 
the adjacent tumour regions exactly where cells with PAX6 and their very neighbours without 
PAX6 resided. These cells could have been processed into RNA-cDNA, and used for comparative 
qPCR. Such approach has been successfully used by other groups, but it is a technically demanding 
and time consuming method. Advantage of this method is that it allows studying the transcriptome 
of "real cancer cells" - meaning malignant cells in clinical samples. This is in contrast to the well-
known weakness of studies based on cell lines, as they are to a certain extent artificial systems, 
potentially rich in artefacts. 
As well, there is a clear need to confirm regulation of the candidate target genes on protein level by 
means of Western blot and/or in-cell Western (for higher throughput and lower costs) and/or 
confocal microscopy of immunostained cells, to look deeper into possible protein localisation 
changes. A pilot study was performed to investigate the usefulness of in-cell western, but due to the 
limited amount of time we were not able to test this method thoroughly. A figure showing the result 
from the pilot study is included in appendix 1. Data from ICW analysis might potentially be more 
meaningful than data derived from traditional western blot because proteins are detected in their 
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Figure 23: In Cell Western – H460 cells.  Anti-TF in A1-A3 and B1-B3. Anti-
VEGFA in C1-C3 and D1-D3.  Anti-P53 in E1-E3 and F1-F3. Anti-VEGFC in 
G1-G3 and H1-H3. Primary antibody dilution in A1-A3, C1-C3, E1-E3 and G1-
G3: 1:300. Primary antibody dilution in B1-B3, D1-D3, F1-F3 and H1-H3: 
1:600. Secondary antibody dilution in A1-H1: 1:500, A2-H2: 1:1000 and A3-
H3: 1:2000. 
